KNSA

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

46.07

USD

KNSA Earnings Reports

Positive Surprise Ratio

KNSA beat 18 of 31 last estimates.

58%

Next Report

Date of Next Report

Apr 21, 2026

Estimate for Q1 26 (Revenue/ EPS)

$211.40M

$0.29

Implied change from Q4 25 (Revenue/ EPS)

+4.59%

+70.59%

Implied change from Q1 25 (Revenue/ EPS)

+53.43%

+163.64%

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares earnings per share and revenue

On Feb 24, 2026, KNSA reported earnings of 0.17 USD per share (EPS) for Q4 25, missing the estimate of 0.38 USD, resulting in a -55.49% surprise. Revenue reached 202.13 million, compared to an expected 198.91 million, with a 1.62% difference. The market reacted with a -8.21% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 6 analysts forecast an EPS of 0.29 USD, with revenue projected to reach 211.40 million USD, implying an increase of 70.59% EPS, and increase of 4.59% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Legend Biotech Corporation - ADR

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.11

Actual

-$0.08

Surprise

+27.73%

Mineralys Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.54

Actual

-$0.40

Surprise

+26.40%

Corvus Pharmaceuticals, Inc.

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.13

Actual

-$0.15

Surprise

-13.72%

Pharming Group N.V. ADS, each representing 10 ordinary shares

Report Date

Mar 12, 2026 For Q4 25

Estimate

$0.00

Actual

$0.01

Surprise

+16.28%

Kamada Ltd

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.07

Actual

$0.06

Surprise

-24.15%

Allogene Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.22

Actual

-$0.17

Surprise

+22.73%

Molecular Partners AG - ADR

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.32

Surprise

+7.09%

Whitehawk Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.15

Actual

-$0.34

Surprise

-116.42%

Codexis, Inc.

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.04

Actual

$0.11

Surprise

+357.01%

Spruce Biosciences, Inc. Common Stock

Report Date

Apr 13, 2026 For Q4 25

Estimate

-$8.14

Actual

Surprise

FAQ

What were Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares reported EPS of $0.17, missing estimates by -55.49%, and revenue of $202.13M, 1.62% above expectations.

How did the market react to Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Q4 2025 earnings?

The stock price moved down -8.21%, changed from $47.39 before the earnings release to $43.50 the day after.

When is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares expected to report next?

The next earning report is scheduled for Apr 21, 2026.

What are the forecasts for Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's next earnings report?

Based on 6 analysts, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares is expected to report EPS of $0.29 and revenue of $211.40M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.